[The technology for manufacturing antiparasitic preparations. 6. The development of a technology for producing the anthelmintic Azinox (praziquantel) and the evaluation of its toxic and anthelmintic properties].
The paper outlines a procedure for manufacturing the anthelminthic Azinox (biltricide) using the new interfacial transfer catalyst benzyl-di-propyl (beta-hydroxyethyl)ammonium chloride. Azinox has been shown to be identical to biltricide (praziquantel) in its properties. Azinox tests on models of Opisthorchis felineus in golden hamsters and of Hymenolepis nana in albino outbred mice have indicated that the agent is not inferior to biltricide in its antitrematodal and anticestodal activities. Azinox displayed a high activity at the preimaginal stages of O. felineus and H. nana and at the larval stage of H.nana.
Mikhaĭlitsyn
F S
FS
Sergovskaia
N L
NL
Lebedeva
M N
MN
Astaf'ev
B A
BA
Gitsu
G A
GA
Baiandina
D G
DG
Uvarova
N A
NA
Lychko
N D
ND
D000818:Animals; D000923:Anticestodal Agents / Q000138:chemical synthesis* / Q000627:therapeutic use / Q000633:toxicity; D000980:Antiplatyhelmintic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use / Q000633:toxicity; D006224:Cricetinae; D004353:Drug Evaluation, Preclinical; D005260:Female; D006925:Hymenolepiasis / Q000188:drug therapy / Q000469:parasitology; D007928:Lethal Dose 50; D008297:Male; D008647:Mesocricetus; D051379:Mice; D009889:Opisthorchiasis / Q000188:drug therapy / Q000469:parasitology; D011223:Praziquantel / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000627:therapeutic use / Q000633:toxicity
D000923:Anticestodal Agents; D000980:Antiplatyhelmintic Agents; C078071:azinox; D011223:Praziquantel